· PRESS RELEASE· PRESS RELEASE· PRESS RELEASE
NEOVACS ANNOUNCES THAT THE POSITIVE RESULTS OF ITS PROOF
OF CONCEPT IN ALLERGIES WITH IL-4 / IL-13 KINOID HAVE
TRIGGERED THE FIRST PAYMENT OF THE ANR GRANT
Paris and Boston, July 9, 2019 - Neovacs - 7:30 am CEST - (Euronext Growth Paris: ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, has today announced having received a first payment within the grant awarded by the National Agency for Research (ANR) representing a total amount up to €702.000 , for its preclinical development program AllergyVacs, conducted in collaboration with Inserm and the Immunology and Allergy Department of Pasteur Institute1.
Neovacs' proof of concept in allergies with its new IL-4 / IL-13 Kinoid therapeutic vaccine was recently presented at two major scientific congresses (Antibodies and Complement 2019 & EAACI2 2019), with a strong interest manifested by the scientific and medical community. The study demonstrated in a representative allergic asthma model that a treatment with IL-4 / IL-13 Kinoid enhanced the production of polyclonal antibodies, which neutralize the two targeted cytokines IL-4 and IL-13, both being development factors for allergic asthma, thus avoiding the occurrance of symptoms.
The submission of this preclinical results to be published in a scientific publication is actually ongoing.
About Neovacs
Listed on Euronext Growth since 2010, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform
Contacts
| NEOVACS Corporate Communication & Investor Relations Charlène Masson +33 1 53 10 93 00 cmasson@neovacs.com (mailto:ntrepo@neovacs.com) | NEWCAP - Media Annie-Florence Loyer Tél : +33 (0)6 88 20 35 59 / +33 (0)1 44 71 00 12 afloyer@newcap.fr (mailto:afloyer@newcap.fr) Léa Jacquin Tel : +33(0)1 44 71 20 41 ljacquin@newcap.fr | ORPHEON FINANCE Financial Communication and Investor Relations James Palmer +33 7 60 92 77 74 j.palmer@orpheonfinance.com (mailto:j.palmer@orpheonfinance.com) |
1 Cf. Press Release published January 8 , 2019 https://bit.ly/2Jo65TO
2 European Academy of Allergy and Clinical Immunology Annual Congress
Attachment
- Press release (https://ml-eu.globenewswire.com/Resource/Download/5aaae403-9f30-4dee-8a38-de26abb58269)
